Sophie Tartas

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Journal: Clinical genitourinary cancer

Published: September 29, 2025

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2025

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 14, 2025

Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.

Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 24, 2024

Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board.

Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board.

Journal: JCO oncology practice

Published: July 22, 2024

Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma.

Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma.

Journal: Lancet (London, England)

Published: March 20, 2024

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

Journal: Cancer chemotherapy and pharmacology

Published: April 01, 2022

Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.

Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: April 01, 2022

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer.

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancers

Published: October 26, 2021

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

Journal: Cancers

Published: September 29, 2021

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

Journal: Clinical genitourinary cancer

Published: December 17, 2020

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

Journal: European urology oncology

Published: October 20, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026